Testosterone Enanthate in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Guidance

What Is Testosterone Enanthate and How Is It Classified for Adolescents?

Testosterone enanthate is a long-acting esterified androgen administered by intramuscular injection. The FDA approved it for hypogonadism and for constitutional delay of growth and puberty (CDGP) in males, but the approved labeling does not cover gender-affirming use or most nuanced hypogonadal sub-diagnoses seen in adolescent practice. Any application outside those narrow indications is, by definition, off-label.

FDA-Approved vs. Off-Label Boundaries

The FDA package insert for testosterone enanthate (Delatestryl) lists two approved pediatric male indications: hypogonadism caused by testicular failure, and CDGP as a short-course stimulant. The insert does not address female patients, non-binary patients, or adolescents with partial androgen deficiency. Clinicians prescribing for any of those groups are acting outside approved labeling, which is legal but requires documented clinical rationale and informed consent [1].

Why Off-Label Prescribing Exists in This Age Group

Published surveys of pediatric endocrinologists show that off-label androgen use in adolescents is well-established clinical practice, not experimental fringe medicine. The Endocrine Society's 2017 clinical practice guideline on gender dysphoria states: "We recommend initiating sex hormone treatment to induce the pubertal transition in a developmentally appropriate timeline." [2] That recommendation explicitly covers testosterone in transmasculine youth, despite no FDA approval for that indication.

Constitutional Delay of Growth and Puberty: The On-Label Starting Point

CDGP is the most common reason a pediatric endocrinologist reaches for testosterone enanthate in an adolescent male. Boys with no signs of puberty by age 14, confirmed by bone age <12 years on wrist X-ray and low-normal LH/FSH, fit the diagnostic profile. The condition is generally benign and self-resolving, but psychological distress from peer comparison is substantial [3].

Dosing for CDGP

Standard practice, as described in a 2021 review in the Journal of Clinical Endocrinology and Metabolism, uses 50 to 100 mg IM every 4 weeks for 3 to 6 months, then reassessing spontaneous gonadotropin rise [4]. The short treatment window minimizes epiphyseal exposure. Doses above 100 mg/month in early puberty carry meaningful risk of accelerating bone maturation faster than linear growth, reducing adult height potential.

Monitoring During CDGP Courses

• Bone age X-ray at baseline and after each 6-month treatment course
• Serum total testosterone at trough (just before next injection) to verify levels stay in early-pubertal range (roughly 100 to 300 ng/dL)
• LH and FSH at 3 months to confirm the hypothalamic-pituitary axis is waking up spontaneously
• Height velocity every 6 months

A 2019 cohort study (N=83) published in the European Journal of Endocrinology found that 3-month testosterone enanthate courses at 100 mg/month increased height velocity by 4.2 cm/year without significant bone-age advancement when trough testosterone stayed below 300 ng/dL [5].

Hypogonadism Beyond CDGP: Organic Causes in Adolescents

Adolescents with Klinefelter syndrome (47,XXY), prior chemotherapy, or testicular torsion have permanent primary hypogonadism. For them, testosterone replacement is lifelong and begins at puberty onset, typically around age 12 to 14. The off-label element here is that the FDA label does not specify pediatric-weight-based dosing tables or developmental-stage titration schedules.

Klinefelter Syndrome Protocol

Boys with Klinefelter syndrome often present with delayed or incomplete puberty. The American Association of Clinical Endocrinology (AACE) supports initiating testosterone at the age-appropriate pubertal stage, not at a fixed chronological age [6]. A common approach:

• Age 12 to 13 (Tanner I/II): 25 to 50 mg IM every 4 weeks
• Age 14 to 15 (Tanner II/III): 75 to 100 mg IM every 4 weeks
• Age 16 to 17 (Tanner III/IV): 100 to 150 mg IM every 2 to 4 weeks, titrating toward adult replacement targets

Serum testosterone targets during titration aim for mid-pubertal values (200 to 500 ng/dL trough) rather than adult male ranges, to allow bone mineralization to proceed at a physiologically appropriate pace.

Post-Chemotherapy Gonadal Failure

Pediatric oncology patients who received alkylating agents (cyclophosphamide, busulfan) or testicular radiation face gonadal failure rates of 30 to 60% depending on cumulative dose [7]. For these patients, testosterone enanthate provides both pubertal induction and long-term androgenic support. Baseline FSH above 20 IU/L and low inhibin B confirm primary testicular damage and justify indefinite replacement.

Gender-Affirming Hormone Therapy: The Largest Off-Label Use

Gender-affirming testosterone therapy for transmasculine adolescents (assigned female at birth, identifying as male or non-binary) represents the most discussed off-label application in this age group. It is also the most thoroughly guideline-supported off-label use, backed by both the Endocrine Society and the World Professional Association for Transgender Health (WPATH).

WPATH Standards of Care Version 8 (2022)

WPATH SOC-8, published in the International Journal of Transgender Health in 2022, removed the minimum age threshold for hormone initiation that had existed in prior versions. The document states: "We recommend health care professionals confirm the adolescent has been informed of the reproductive effects of hormone therapy and has either consented or assented to treatment with parental or guardian permission." [8] This represents a shift toward individualized readiness assessment rather than age cutoffs.

Endocrine Society 2017 Guideline Position

The Endocrine Society guideline recommends starting gender-affirming hormones "after a multidisciplinary team has confirmed persistent gender dysphoria and the absence of psychiatric comorbidities that would interfere with treatment." [2] Testosterone enanthate is explicitly listed as an appropriate androgen formulation. The guideline does not endorse a specific minimum age but ties initiation to Tanner stage and psychological readiness.

Typical Gender-Affirming Dosing in Adolescents

Starting doses are lower than adult replacement doses to allow gradual virilization and psychological adjustment:

• Initial: 25 to 50 mg IM every 2 to 4 weeks
• After 6 months: 50 to 75 mg IM every 2 weeks if response and tolerability are good
• Adult doses (100 mg every 2 weeks or equivalent): typically reached over 18 to 24 months

A stepwise titration framework used at several academic pediatric gender programs titrates based on three concurrent signals: (1) trough serum testosterone entering the target range of 300 to 700 ng/dL, (2) patient-reported satisfaction with virilization rate, and (3) absence of hematocrit elevation above 50%. Dose escalation is paused if any signal is out of range.

Physical Changes and Timelines

Adolescents and families should have realistic expectations. Voice deepening and clitoral enlargement begin within 3 to 6 months. Facial hair typically appears at 6 to 12 months but may take 3 to 5 years to develop density. Body fat redistribution toward a masculine pattern occurs over 1 to 2 years. Menstrual cessation happens in roughly 50% of patients within 6 months at doses above 50 mg every 2 weeks [9].

Safety Profile Specific to Adolescents

The safety profile of testosterone enanthate in adolescents shares features with adult use but carries several age-specific concerns that require distinct monitoring strategies.

Bone Health and Epiphyseal Closure

This is the single most age-specific risk. Testosterone aromatizes to estradiol, which drives epiphyseal fusion. Excessive testosterone doses before bone age reaches 14 to 15 years can close growth plates prematurely and reduce final adult height. Bone-age X-rays every 6 months are not optional; they are the primary safety gate for dose escalation in adolescents who have not yet reached full skeletal maturity [4].

In a 2020 retrospective study of 101 transmasculine adolescents initiating testosterone (mean age 15.8 years), bone mineral density Z-scores at the lumbar spine were stable at 12 months and slightly improved at 24 months, suggesting that properly dosed testosterone does not harm bone accrual in mid-to-late adolescence [10].

Polycythemia and Cardiovascular Risk

Testosterone stimulates erythropoiesis. Hematocrit above 52% increases blood viscosity and thrombotic risk. Adolescents on testosterone should have hematocrit checked at every lab visit (every 3 to 6 months). Hematocrit above 50% warrants dose reduction or extended injection interval before considering therapeutic phlebotomy.

Lipid Changes

Testosterone consistently lowers HDL cholesterol and may raise LDL. A 2021 systematic review in Pediatrics (N=464 adolescent transgender males) found mean HDL fell by 8.2 mg/dL at 12 months of testosterone therapy, while LDL changes were variable [11]. Fasting lipids should be checked at baseline and at 12 months, then annually.

Psychological Monitoring

Gender-affirming testosterone has been associated with significant improvement in depression and anxiety scores in adolescents. A prospective study (N=315) published in NEJM in 2023 found that gender-affirming care including hormones was associated with 60% lower odds of moderate-to-severe depression at 12 months compared to baseline (odds ratio 0.40, 95% CI 0.22 to 0.73, P<0.01) [12]. Psychological support remains part of the treatment package, not a prerequisite replaced by hormones alone.

Consent, Assent, and Legal Considerations

Adolescent medicine operates under a dual consent structure. Parents or legal guardians provide consent; the adolescent provides assent, meaning their own affirmative agreement after age-appropriate explanation. Mature minor doctrines in some U.S. States allow adolescents 16 or older to consent independently to medical care, but this varies significantly by jurisdiction.

What Informed Consent Must Cover

Before initiating off-label testosterone enanthate in any adolescent, the prescribing clinician must document that the patient and guardian understand:

1. The off-label status of the specific indication
2. Fertility effects (transmasculine patients should know that testosterone suppresses ovulation but does not guarantee contraception and does not prevent pregnancy)
3. Permanence and reversibility of specific changes (voice changes are permanent; some others are partially reversible)
4. The long-term monitoring commitment required

The Endocrine Society guideline specifically recommends fertility counseling and, where desired, referral for oocyte or sperm cryopreservation before starting hormones [2].

Documentation Standards

Clinicians should document the clinical reasoning for off-label use in the medical record, including why approved alternatives were considered inadequate or inapplicable. This protects the patient and the prescriber in any subsequent audit.

Formulation Considerations: Why Enanthate Specifically

Testosterone enanthate is not the only testosterone formulation available. Testosterone cypionate has a very similar half-life (approximately 8 days vs. 7.9 days for enanthate) and is often substituted interchangeably. Testosterone undecanoate (Aveed) carries FDA approval for adult males only and is not used in pediatric populations. Topical gels are sometimes preferred in adolescents who are needle-averse, but gel absorption in adolescents is less predictable and transfer risk to family members is a real concern [1].

Enanthate's 2 to 4 week injection interval makes it practical for adolescent patients who can receive injections at home or in a clinic. Self-injection training, typically taught by a nurse educator, is appropriate for motivated adolescents above age 14.

Current Guideline Field and Controversies

The off-label use of testosterone in adolescents sits at the intersection of endocrinology, adolescent medicine, and ongoing societal debate. Clinicians should be aware of both the guideline endorsements and the areas of genuine scientific uncertainty.

What the Guidelines Agree On

• Testosterone enanthate is an appropriate androgen for pubertal induction in males with hypogonadism (Endocrine Society, AACE)
• Gender-affirming testosterone is supported for adolescents meeting diagnostic and readiness criteria (Endocrine Society 2017, WPATH SOC-8 2022)
• Multidisciplinary team involvement is standard of care, not optional

Areas of Ongoing Research

Long-term data on gender-affirming testosterone initiated in early adolescence (ages 12 to 14) are limited. Most cohort studies have follow-up periods of 2 to 5 years. The impact on final height, fertility, and cardiovascular outcomes over decades is not yet fully characterized. A 2022 Cochrane review on hormonal treatment for gender dysphoria in adolescents identified only low-to-moderate quality evidence across 13 studies, citing small sample sizes and lack of randomized controlled trial data as primary limitations [13].

State-Level Legal Restrictions in the U.S.

As of 2025, more than 20 U.S. States have enacted laws restricting or banning gender-affirming hormone therapy for minors. Clinicians must verify current state law before prescribing. In states where care is restricted, adolescents and families may need referral to providers in jurisdictions where the care remains legal.

Practical Prescribing Checklist for Off-Label Testosterone Enanthate in Adolescents

Before writing the first prescription, a clinician should confirm:

• Confirmed diagnosis documented (CDGP, hypogonadism, or gender dysphoria with ICD-10 code)
• Bone age X-ray obtained within the past 6 months
• Baseline labs drawn: total testosterone, LH, FSH, CBC with hematocrit, fasting lipids, liver function tests
• Informed consent and assent documents signed and filed
• State law verified for the specific indication
• Mental health provider identified and coordinating (required for gender-affirming use)
• Injection training arranged if self-administration is planned
• Follow-up appointment scheduled at 3 months

Starting dose selected per indication:

• CDGP: 50 to 100 mg IM every 4 weeks for 3 to 6 months
• Organic hypogonadism: 25 to 50 mg IM every 4 weeks, titrating to Tanner stage
• Gender-affirming: 25 to 50 mg IM every 2 to 4 weeks, titrating to testosterone trough target and patient response